Latest Updates
Read the latest news that impacts the oncology community.
- Published On: July 11th, 2024
CMS just released the latest Physician Fee Schedule Rule (PFS). COA is conducting an in-depth analysis of the rule and will provide further detail once that is complete.
- Published On: July 11th, 2024
The Biden administration is proposing a 2.8% decrease to physician payments in its newly released pay proposal for physicians, drawing near-immediate protest from the industry.
- Published On: July 11th, 2024
Medicare physician payments would decline 2.9% in 2025 under a proposed rule the Centers for Medicare and Medicaid Services published Wednesday.
- Published On: July 11th, 2024
The Federal Trade Commission plans to sue the three largest pharmacy benefit managers over their negotiating tactics for various medicines, including insulin, that pushed patients toward higher-priced treatments, according to a source familiar with the matter.
- Published On: July 10th, 2024
Firms that manage drug benefits, which promise to keep a lid on high drug costs, instead steer patients away from less expensive medicines and overcharge for cancer therapies, Federal Trade Commission investigators found.
- Published On: July 10th, 2024
The interim FTC report released Tuesday said PBMs wield enormous power on the accessibility and affordability of prescription drugs, and “these powerful middlemen may be profiting by inflating drug costs and squeezing Main Street pharmacies.”
- Published On: July 10th, 2024
Pharmacy benefit managers (PBMs), the so-called drug “middlemen” that were created with the mission of reining in costs, appear to have had the opposite effect for the American consumer—driving up drug costs, pushing the independent pharmacist into oblivion, and creating incentives that crush low-cost options such as generics and biosimilars, according to a scathing report issued by the Federal Trade Commission (FTC).
- Published On: July 10th, 2024
Prescription drug middlemen — also known as pharmacy benefit managers — are lining their pockets by inflating drug prices, including overcharging cancer patients, the Federal Trade Commission said Tuesday.
- Published On: July 10th, 2024
Drug middlemen, known as pharmacy-benefit managers, have accomplished something rare in Washington: Their business practices have led to a bipartisan consensus of sorts around the need for more regulation.
- Published On: July 9th, 2024
The Federal Trade Commission today published an interim report on the prescription drug middleman industry that underscores the impact pharmacy benefit managers (PBMs) have on the accessibility and affordability of prescription drugs.